{"nctId":"NCT00101582","briefTitle":"Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer","startDateStruct":{"date":"2005-08"},"conditions":["Mucositis","Solid Tumors","Stomatitis","Head and Neck Cancer","Squamous Cell Carcinoma"],"count":188,"armGroups":[{"label":"Palifermin","type":"EXPERIMENTAL","interventionNames":["Drug: palifermin","Drug: cisplatin chemotherapy","Radiation: Radiotherapy"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: cisplatin chemotherapy","Radiation: Radiotherapy"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"palifermin","otherNames":["Kepivance","Recombinant Human Keratinocyte Growth Factor (rHuKGF)"]},{"name":"cisplatin chemotherapy","otherNames":[]},{"name":"Radiotherapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Histologically documented squamous cell carcinoma involving either the oral cavity, oropharynx, nasopharynx, hypopharynx, or larynx\n* Newly diagnosed, locally advanced stage head and neck cancer (unresectable/unresected disease); American Joint Committee on Cancer \\[AJCC\\] Stage III, IVA or IVB amenable to radiotherapy with concurrent chemotherapy as the definitive treatment modality\n* At least 50 Gray of radiation treatment to areas of the oral cavity/oropharynx mucosa that can be visualized\n* Concurrent chemotherapy regimen of Cisplatin 100mg/m\\^2 on days 1, 22, and 43\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) less than or equal to 2\n* Adequate hematologic, renal and hepatic function\n* Negative pregnancy test by serum or urine\n* Signed informed consent\n\nKey Exclusion Criteria:\n\n\\- Presence or history of any other primary malignancy (other than curatively treated in situ cervical cancer, or basal cell carcinoma of the skin without evidence of disease for greater than 3 years)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Severe (Grade 3 or 4) Oral Mucositis","description":"Participants underwent evaluations of oral mucosal (OM) surfaces (mucositis assessments) 2 times weekly throughout radio/chemotherapy, and 2 times weekly thereafter until severe OM returned to grade ≤ 2 or until Week 15. During each evaluation, the following anatomical areas were assessed: upper lip; lower lip; right cheek; left cheek; right ventral \\& lateral tongue; left ventral \\& lateral tongue; floor of the mouth; hard palate; soft palate. A trained evaluator documented the findings using the World Health Organization (WHO) oral toxicity scale according to the following: Grade 0 = None; Grade 1 = Soreness, erythema; Grade 2 = Erythema, ulcers, ability to eat solids; Grade 3 = Ulcers, requires liquid diet; Grade 4 = Alimentation not possible.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Severe (WHO Grade 3 or 4) Oral Mucositis","description":"The duration of severe oral mucositis (OM) was calculated as the number of days from the onset of severe OM (first time a WHO grade 3 or 4 was observed) to the day when severe OM was resolved (first time WHO grade 2 or less was observed after last WHO grade 3 or 4). Durations of 0 days were assigned to those participants who did not experience any WHO grade 3 or 4 during the study.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.0","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Onset of Severe (WHO Grade 3 or 4) Oral Mucositis","description":"Time to onset of severe (WHO Grade 3 or 4) oral mucositis (OM) was analyzed using the Kaplan-Meier procedure.\n\nParticipants without an assessed event by the end of the acute OM evaluation phase were censored at the date of last assessment for severe OM.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":null},{"groupId":"OG001","value":"47.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Xerostomia at Month 4 (Grade 2 or Higher)","description":"The number of participants with grade 2 or higher xerostomia (dryness of the oral mucosa) at the Month 4 visit, graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 Dry Mouth/Xerostomia scale.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-Reported Mouth and Throat Soreness Score","description":"The average patient-reported mouth and throat soreness (MTS) score as reported on question 3 of the Oral Mucositis Weekly Questionnaire for Head and Neck Cancer \\[OMWQ-HN\\]): \"How much mouth and throat soreness did you experience in the past 24 hours?\" Participants answered on a scale from 0 (no soreness) to 4 (extreme soreness).\n\nFor each participant, an average patient-reported mouth and throat soreness score was calculated by dividing the sum of the MTS scores at each assessment by the total number of assessments.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.86","spread":"0.65"},{"groupId":"OG001","value":"1.66","spread":"0.73"}]}]}]},{"type":"SECONDARY","title":"Total Dose of Opioid Analgesics Used for Mucositis Within 15 Weeks","description":"The total dose of opioid analgesics (mg of intravenous \\[IV\\] morphine equivalents) used by all participants.\n\nParticipants with at least one reported administration of opioid analgesic (parenteral, peroral or transdermal) were considered to have received opioid analgesics. The total dose of opioid analgesics is the sum of all opioid analgesic administrations that have been converted to morphine equivalents.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1219.55","spread":"1769.29"},{"groupId":"OG001","value":"1243.31","spread":"2700.28"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Unplanned Breaks in Cisplatin Chemotherapy Treatment","description":"Cisplatin was administered on Days 1, 22, and 43. An unplanned break in cisplatin refers to a delay of ≥ 5 days from the scheduled Day 22 or Day 43 cisplatin administration or a discontinuation of cisplatin for any reason.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Unplanned Breaks in Radiotherapy","description":"Participants with a duration of 5 days or more without an administration of radiotherapy or who discontinue radiotherapy prior to completion of planned radiotherapy were considered to have an unplanned break in radiotherapy.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":25,"n":91},"commonTop":["Nausea","Constipation","Anaemia","Weight decreased","Vomiting"]}}}